Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros

Intervalo de año
1.
medrxiv; 2023.
Preprint en Inglés | medRxiv | ID: ppzbmed-10.1101.2023.08.09.23293901

RESUMEN

Objective: To characterize subphenotypes of self-reported symptoms and outcomes(SRSOs) in Post-acute sequelae of COVID-19(PASC). Design: Prospective, observational cohort study of PASC subjects. Setting: Academic tertiary center from five clinical referral sources. Participants: Adults with COVID-19 [≥] 20 days before enrollment and presence of any new self-reported symptoms following COVID-19. Exposures: We collected data on clinical variables and SRSOs via structured telephone interviews and performed standardized assessments with validated clinical numerical scales to capture psychological symptoms, neurocognitive functioning, and cardiopulmonary function. We collected saliva and stool samples for quantification of SARS-CoV-2 RNA via qPCR. Primary and Secondary outcomes of measure: Description of PASC SRSOs burden and duration, derivation of distinct PASC subphenotypes via latent class analysis (LCA), and relationship between viral load with SRSOs and PASC subphenotypes. Results: Baseline data for 214 individuals were analyzed. The study visit took place at a median of 197.5 days after COVID-19 diagnosis, and participants reported ever having a median of 9/16 symptoms (interquartile range 6-11) after acute COVID, with muscle-aches, dyspnea, and headache being the most common. Fatigue, cognitive impairment, and dyspnea were experienced for a longer time. Participants had a lower burden of active symptoms (median 3, interquartile range 1-6) than those ever experienced (p<0.001). Unsupervised LCA of symptoms revealed three clinically-active PASC subphenotypes: a high burden constitutional symptoms (21.9%) , a persistent loss/change of smell and taste (20.6%) , and a minimal residual symptoms subphenotype (57.5%). Subphenotype assignments were strongly associated with self-assessments of global health, recovery and PASC impact on employment (p<0.001). Viral persistence (5.6% saliva and 1% stool samples positive) did not explain SRSOs or subphenotypes. Conclusions: We identified distinct PASC subphenotypes and highlight that although most symptoms progressively resolve, specific PASC subpopulations are impacted by either high burden of constitutional symptoms or persistent olfactory/gustatory dysfunction, requiring prospective identification and targeted preventive or therapeutic interventions.


Asunto(s)
Dolor , Cefalea , Disnea , COVID-19 , Convulsiones , Disfunciones Sexuales Psicológicas , Trastornos del Conocimiento
2.
ClinicalTrials.gov; 27/10/2022; TrialID: NCT05597722
Clinical Trial Register | ICTRP | ID: ictrp-NCT05597722

RESUMEN

Condition:

Cognitive Impairment;Long COVID

Intervention:

Behavioral: Digital cognitive behavioral intervention-RxWell;Drug: Amphetamine-Dextroamphetamine

Primary outcome:

Change in Cognitive Impairment - MOCA;Change in Cognitive Impairment - BrainCheck;Change in Cognitive Impairment - ImPACT

Criteria:


Inclusion Criteria:

- History of SARS-CoV-2 infection as defined as a positive PCR or home antigen test

- Patients with Long-COVID as defined as COVID symptoms that persist for three months or
longer.

- Between the ages of 21 and 65

- Moderate cognitive impairment (MOCA score to meet criteria is < or =18) present for at
least 3 months

- Response of "No" to the screening question, "Are you pregnant or do you plan to become
pregnant in the next 3 months?"

- Access to a smartphone

Exclusion Criteria:

- History of dementia, psychosis, mania, addiction or current conditions requiring
immediate hospitalization

- Previous adverse or allergic reaction to Adderall or other amphetamines

- Pre-existing cardiac or kidney condition, severe hypertension, glaucoma, advanced
arteriosclerosis, hyperthyroidism, and taking an MAOI within the past 14 days

- Current or past substance misuse

- Previous use of RxWell (completed 3 or more techniques)

- Current use of amphetamine-dextroamphetamine

- History of uncontrolled blood pressure

- Subjects taking Methylphenidate; Lisdexamfetamine; non-Adderall amphetamine products;
Atomoxetine; Viloxazine; Modafinil; Armodafinil; Nortriptyline and other tricyclic
drugs; Bupropion; Tramadol; and Monoamine Oxidase Inhibitor (MAOI) drugs (including
Linezolid).

- Inability to pay for study medication.


SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA